Mechanism of Action for Xaluritamig

Xaluritamig is a novel T-cell engager immunotherapy being developed for advanced prostate cancer. Xaluritamig is designed to activate the immune system against prostate cancer cells by creating an immune synapse between immune T cells and STEAP1, a protein that is uniquely overexpressed in prostate cancer cells.^1-3 

 Watch this video to learn more about the mechanism of action of Xaluritamig.

1. Kelly WK, Danila DC, Lin CC, et al. Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. Cancer Discov. 2024;14(1):76-89. doi: 10.1158/2159-8290

2. Nolan-Stevaux O, Li C, et al. AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer. Cancer Discov. 2024 Jan 12;14(1):90-103. doi: 10.1158/2159-8290

3. Xu M, Evans L, Bizzaro CL, et al. STEAP1-4 (Six-Transmembrane Epithelial Antigen of the Prostate 1-4) and Their Clinical Implications for Prostate Cancer. Cancers (Basel). 2022;14(16):4034. doi: 10.3390/cancers14164034

/Reusable Clone Sites/Patient Site/Standard O-US Site/Home/Download Page1/Resource1

Αποχωρείτε από αυτόν τον ιστότοπο

Αποχωρείτε από αυτόν τον ιστότοπο και εισέρχεστε σε άλλο ιστότοπο. Η Amgen δεν είναι υπεύθυνη για το περιεχόμενο ή την υιοθέτηση τέτοιου περιεχομένου σε αυτόν τον ιστότοπο.

Επιστροφή Συνέχεια